The United Laboratories International Holdings (3933) AI Stock Analysis

• Market Cap: HK$28.73B
• Dividend Yield: 4.1%
• Average Volume (3M): 18.02M
• Price to Earnings (P/E): 9.2
• Beta (1Y): 0.69
• Revenue Growth: -1.82%
• EPS Growth: -3.34%
• Country: HK
• Employees: 17,000
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.70
• Shares Outstanding: 1,973,026,500
• 10 Day Avg. Volume: 26,765,426
• 30 Day Avg. Volume: 18,024,838
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$17.03
• Price Target Upside: 15.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 75 Outperform
• Price Target: HK$18.00 ▲(22.53%Upside)

The stock is favorably positioned with strong financial performance, particularly in profitability and balance sheet strength. Positive technical indicators further support its appeal. The valuation is attractive with a reasonable P/E ratio and a solid dividend yield. However, the absence of recent earnings call data limits comprehensive analysis of future outlook and sentiment.

The United Laboratories International Holdings Business Overview & Revenue Model

Company Description

The United Laboratories International Holdings Limited (3933) is a leading pharmaceutical company based in China, specializing in the development, manufacturing, and distribution of a wide range of pharmaceutical products. The company operates primarily in the sectors of antibiotics, insulin, and other prescription and over-the-counter medications. It is recognized for its comprehensive production chain that includes raw materials, intermediates, and finished products, ensuring quality control and cost efficiency.

How the Company Makes Money

The United Laboratories International Holdings makes money primarily through the sale of its pharmaceutical products. Its revenue streams are diversified across various product lines, including antibiotics, insulin, and other therapeutic drugs. The company benefits from economies of scale due to its vertically integrated production process, which allows it to manage costs effectively while maintaining product quality. Significant partnerships include collaborations with healthcare providers and distribution networks that help in expanding its market reach both domestically and internationally. Additionally, research and development investments contribute to the company's ability to innovate and introduce new products, further driving revenue growth.

The United Laboratories International Holdings Financial Statement Overview

Summary

The company exhibits strong revenue and profit growth with robust profitability margins and a solid balance sheet featuring low financial leverage. However, cash flow management needs improvement due to recent data inconsistencies and fluctuations.

Income Statement

The company has demonstrated consistent revenue growth over the years, with a notable increase from 2022 to 2023. The gross profit margin and net profit margin are robust, indicating strong profitability. Although EBIT and EBITDA margins slightly decreased in 2024, they remain healthy, reflecting effective cost management and operational efficiency.

Balance Sheet

The balance sheet shows a strong equity position with a growing stockholders' equity base, contributing to a favorable equity ratio. The debt-to-equity ratio is low, indicating prudent financial leverage and reduced financial risk. However, the return on equity has experienced minor fluctuations, suggesting potential efficiency improvements.

Cash Flow

The cash flow statement reveals fluctuating free cash flow figures, with a significant drop in 2024 due to unavailable operating cash flow data. The historical trend shows a positive operating cash flow to net income ratio, but recent data gaps hinder comprehensive assessment. Free cash flow management needs stabilization for improved financial health.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.76B	13.74B	11.33B	9.70B	8.77B
Gross Profit	6.08B	6.33B	4.97B	4.21B	3.81B
EBITDA	3.35B	3.98B	2.54B	1.98B	1.83B
Net Income	2.66B	2.70B	1.58B	988.10M	702.99M
Balance Sheet
Total Assets	25.83B	21.02B	18.98B	16.33B	14.96B
Cash, Cash Equivalents and Short-Term Investments	6.33B	4.26B	4.74B	3.33B	3.00B
Total Debt	3.16B	1.50B	2.46B	1.84B	2.21B
Total Liabilities	11.40B	8.27B	8.37B	6.99B	6.35B
Stockholders Equity	14.39B	12.73B	10.61B	9.34B	8.61B
Cash Flow
Free Cash Flow	1.33B	977.50M	1.25B	1.06B	1.04B
Operating Cash Flow	3.20B	2.44B	2.03B	1.54B	1.57B
Investing Cash Flow	-1.73B	-1.56B	-594.92M	-587.22M	166.76M
Financing Cash Flow	596.91M	-1.36B	-24.17M	-620.93M	-1.91B

The United Laboratories International Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 14.69
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3933, the sentiment is Neutral. The current price of 14.69 is below the 20-day moving average (MA) of 15.09, below the 50-day MA of 15.01, and above the 200-day MA of 12.70, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 45.32 is Neutral, neither overbought nor oversold. The STOCH value of 14.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:3933.

The United Laboratories International Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3933	75 Outperform	HK$28.73B	9.17	19.62%	4.10%	-1.82%	-3.34%
1513	74 Outperform	$38.97B	15.15	14.56%	3.20%	-5.37%	6.28%
0512	71 Outperform	HK$29.82B	11.92	15.61%	3.10%	10.59%	31.83%
0867	71 Outperform	$31.71B	17.97	10.17%	4.49%	-8.91%	-34.40%
0013	63 Neutral	£23.81B	80.82	5.02%	―	-25.07%	-64.03%
3320	62 Neutral	€33.61B	9.25		4.82%	―	―
Sector *	60 Neutral	HK$16.77B	6.05	-6.40%	3.69%	11.62%	-23.89%

The United Laboratories International Holdings Corporate Events

The United Laboratories Completes Successful Share Placement

The United Laboratories International Holdings Limited has successfully completed the placing of 156,000,000 new shares, raising net proceeds of HK$2,168.2 million. The funds will be used primarily for capital expenditure on manufacturing facilities, including the Inner Mongolia and Zhuhai plants, as well as for expanding international business and general corporate purposes.

The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

The United Laboratories Announces Share Placement to Fund Expansion and R&D

The United Laboratories International Holdings Limited has announced a placing of new shares under a general mandate, aiming to raise approximately HK$2,168.2 million in net proceeds. The funds will be allocated towards capital expenditure for expanding manufacturing facilities, enhancing external collaborations, and research and development, including clinical trials for innovative product candidates.

The most recent analyst rating on (HK:3933) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

United Laboratories’ Antibiotic Injection Passes Key Evaluation

The United Laboratories International Holdings Limited announced that its product, Amoxicillin Sodium and Clavulanate Potassium for Injection, has passed the Consistency Evaluation by the China National Medical Products Administration. This approval is expected to strengthen the company’s position in the anti-infective field and enhance its market presence, while continuing to focus on research and development for future growth.

The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

FDA Approves United Laboratories’ Innovative Drug for Obesity

The United Laboratories International Holdings Limited announced the FDA approval of its investigational new drug application for UBT37034 Injection, a Class 1 innovative drug targeting overweight and obesity. This approval marks a significant step for the company in enhancing its competitiveness and creativity within the biopharmaceutical industry, potentially benefiting its operations and stakeholders.

The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

The United Laboratories Announces Final Dividend for 2024

The United Laboratories International Holdings Limited announced a final cash dividend of RMB 0.28 per share for the financial year ending December 31, 2024. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.094945, with a payment date set for July 23, 2025. This announcement reflects the company’s stable financial performance and commitment to returning value to its shareholders.

The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

The United Laboratories Announces Special Dividend for 2024

The United Laboratories International Holdings Limited has announced a special dividend of RMB 0.12 per share for the financial year ending 31 December 2024, with payment to be made in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.094945. This announcement reflects the company’s strong financial performance and commitment to providing value to its shareholders, with the payment date set for 23 July 2025.

The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

United Laboratories Announces 2024 Final and Special Dividends

The United Laboratories International Holdings Limited announced the approval of a final dividend of RMB28 cents per share and a special dividend of RMB12 cents per share for the year ending December 31, 2024. These dividends will be converted to Hong Kong dollars and are expected to be paid on July 23, 2025, to shareholders listed on the register as of July 11, 2025. This announcement reflects the company’s commitment to rewarding its shareholders and could positively impact its market positioning by enhancing shareholder value.

The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

United Laboratories’ AGM Resolutions Passed, Affirming Strategic Direction

The United Laboratories International Holdings Limited announced that all proposed resolutions at their 2025 Annual General Meeting were approved by shareholders. Key resolutions included the adoption of financial statements, declaration of dividends, re-election of directors, and granting of mandates related to company securities. This successful AGM reflects shareholder confidence and supports the company’s strategic direction.

The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

United Laboratories Secures $180 Million Upfront Payment from Novo Nordisk

The United Laboratories International Holdings Limited announced that its subsidiary, United Biotechnology, has received an upfront payment of $180 million from Novo Nordisk under an exclusive license agreement for UBT251, a triple agonist in clinical trials for obesity and type 2 diabetes. This agreement also allows United Biotechnology to potentially receive up to $1.8 billion in milestone payments and tiered royalties based on future sales, highlighting a significant financial and strategic boost for the company in the pharmaceutical sector.

The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.